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COMPARATIVE MOLECULAR CHARACTERIZATION OF TYPICAL AND 
EXCEPTIONAL RESPONDERS IN GLIOBLASTOMA 
Kristin Wipfler, Ph.D. 
University of Nebraska, 2017 
Supervisor: Chittibabu Guda, Ph.D. 
Glioblastoma (GBM) is the most common and the deadliest type of primary brain tumor, 
with a median survival time of only 15 months despite aggressive treatment. Although 
most patients have an extremely poor prognosis, a small number of patients survive far 
beyond the median survival time. Investigation of these “exceptional responders” has 
sparked a great deal of interest and is becoming an important focus in the field of cancer 
research. To investigate the molecular differences between typical and exceptional 
responders in GBM, comparative analyses of copy number, methylation, gene expression, 
miRNA expression, and protein expression data sets from The Cancer Genome Atlas were 
performed, and the results of these analyses were integrated via correlation studies and 
pathway analyses to assess the functional significance of the differential aberrations. 
Typical responders are characterized by upregulation of NF-κB signaling and of pro-
inflammatory cytokines and their associated pathways, while exceptional responders are 
characterized by upregulation of Alzheimer’s and Parkinson’s disease pathways, as well 
as of genes involved in synaptic transmission and plasticity. The upregulated pathways 
and processes in typical responders are consistently associated with more aggressive 
tumor phenotypes, while those in the exceptional responders suggest a retained ability in 
tumor cells to undergo cell death. 
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 Glioblastoma (GBM) is the most common and the deadliest type of primary brain 
tumor. GBM is highly malignant and nearly uniformly fatal, with a median survival time 
of only approximately 15 months despite aggressive treatment, including surgical 
resection followed by concurrent radiation and chemotherapy with temozolomide.1–3 
GBM tumors are particularly aggressive due to their high degree of heterogeneity and 
tentacle-like projections that infiltrate surrounding brain tissue, making them extremely 
difficult to fully excise.4,5  
 The central nervous system is comprised of neurons and glia (including astrocytes, 
oligodendrocytes, and microglia).6 GBM arises from astrocytes, star-shaped glial cells that 
play a variety of diverse roles in the central nervous system, including maintenance of 
homeostasis, regulation of blood flow, and synaptic transmission.5,7 GBM usually arises 
in the cerebral hemispheres, but can be found anywhere in the brain or spinal cord. Most 
cases occur sporadically, without genetic predisposition. The only known risk factors are 
some specific genetic diseases (neurofibromatosis, tuberous sclerosis, Li-Fraumeni 
syndrome, retinoblastoma, and Turcot syndrome) and some environmental exposures 
(ionizing radiation, vinyl chloride, pesticides, smoking, petroleum refining, and synthetic 
rubber manufacturing). The most common symptom is a progressive neurological deficit 
resulting in personality changes or memory loss, but headaches and seizures may occur 
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as well. The incidence of GBM is higher in men than in women and presents at a median 
age of 64 years.2  
 There are three pathways that are consistently dysregulated in GBM: the p53 
pathway, the receptor tyrosine kinase/Ras/phosphoinositide 3-kinase signaling pathway, 
and the retinoblastoma pathway. Other common alterations include overexpression of 
EGFR (epidermal growth factor receptor), mutations in PTEN (phosphatase and tensin 
homolog), and loss of chromosome 10.2 Treatment options targeting these genes and 
pathways have been explored, primarily anti-EGFR agents, but their efficacy is limited by 
drug resistance.8 
 
The Cancer Genome Atlas 
 The Cancer Genome Atlas (TCGA) was a project led by the National Cancer 
Institute (NCI) and the National Human Genome Research Institute that began in 2005. It 
was a database that contained genomic data obtained from a variety of high-throughput 
genome analysis techniques for 33 different cancer types. Data types investigated in the 
TCGA project included gene expression profiling, copy number variation, SNP 
genotyping, DNA methylation profiling, and many more. The primary goal of the project 
was to demonstrate that genomic data from a variety of sources could be integrated and 
utilized to identify statistically and biologically significant alterations in cancer.9,10 
 The TCGA project has now concluded, but the more than two petabytes of 
genomic data generated in the project have been made publicly available through the 
Genomic Data Commons (GDC). This massive amount of data provides a unique 
3 
 
opportunity to analyze a variety of data types for a large number of cancer patients. By 
the end of the TCGA project, the GBM dataset included data for 528 patients. The different 
data types included in the GBM dataset were clinical information, gene expression, exon 
expression, miRNA expression, copy number arrays, methylation arrays, SNP arrays, 
trace files, somatic mutations, protein expression, and RNAseq (Table 1).10–12  
 
Exceptional Responders Initiative 
 With the end of the TCGA project, NCI is now developing multiple new genomics 
databases, one of which is the Exceptional Responders Initiative (ERI). The goal of this 
project is to identify molecular features that predict whether or not a particular drug or 
class of drugs will help patients live longer. In many cases, a treatment is deemed 
unsuccessful after a clinical trial, but 10% or fewer of the patients still have a favorable 
response. The ERI project intends to identify markers that predict positive responses in 
such cases. The database will include patients that receive standard treatments as well, 
not just patients in clinical trials.13,14 
 The idea for the ERI came about based on the concept of exceptional responders, 
patients who have a unique response to treatments that are not effective for most other 
patients. The exact definition of “exceptional” varies by specific disease, stage, and 
treatment. In general, exceptional responders achieve a complete or partial response that 
only up to 10% of patients experience, and they sustain that response for a much longer 












Data Type N (full dataset) N (subset) 
Clinical 499 75 
Copy Number (SNP array) 493 72 
Methylation (27k) 287 32 
Gene Expression (DNA microarray) 440 67 
miRNA Expression 474 72 
Protein Expression 210 20 
Table 1: Number of patients in each data type in the TCGA GBM dataset. Of the data types 
available for GBM, seven were analyzed, six of which are discussed in this dissertation. The 
number of patients for each of these data types is listed for the full dataset (499 Total) as well as for 
the dataset analyzed in this work (75 total). The selection of this subset of patients is discussed in 
Chapter 1. The exon expression and copy number array data types were excluded due to 
redundancy with gene expression and SNP arrays, respectively. RNAseq was excluded because 
the available data files were highly processed with a methodology that is not preferred, while the 
gene expression data type was available in a raw format. Trace files were excluded as they are 
outdated, having a been replaced by GAM files. When data were available from multiple platforms 









 Investigating these exceptional responders has become an important focus for the 
future of cancer research. There is a great deal of interest in studying these rare patients 
to learn how to improve therapies for patients who have a more typical response. Several 
studies of exceptional responders have already been published, and they have helped 
uncover molecular alterations and mechanisms of resistance. With the huge amount of 
interest and funding being directed at this topic, it is expected that studies of exceptional 
responders will be a major focus of cancer research in the near future.16–19 
 
Hypothesis 
 Analyzing and integrating the information from the variety of next generation 
sequencing and array-based data available in TCGA (now the GDC) for typical and 
exceptional responders will reveal aberrations that produce more aggressive tumors in 
typical responders as well as protective effects in exceptional responders. This will 
provide a clearer picture of the molecular basis of GBM and also reveal possible 











SURVIVAL ANALYSIS AND DEFINING THE RESPONSE GROUPS 
 
Introduction 
 With current therapies, the median survival time for GBM patients is 
approximately 15 months. Although most patients have an extremely poor outcome, a 
small number of patients survive far beyond the median survival time.1 Survival analyses 
in the current literature often have a very small sample size and look specifically at a very 
small set of genes, such as IDH1 and MGMT or EGFR and TP53.20–23 These studies often 
have arbitrarily chosen survival time cutoffs, typically >36 months for long survival and 
<36 months for short survival. These cutoffs are not appropriate for the study of survival 
outcomes in GBM, as the resulting short survival groups would include many patients 
who survive well beyond the median survival time. Defining survival groups to compare 
based on specific characteristics of GBM and the survival curve of TCGA GBM patients 
would be a vast improvement over the commonly used arbitrary methods described 
above. 
 In addition to an improved method of defining survival groups, a main focus of 
this study is an investigation of so-called “exceptional responders” in GBM. NCI 
researchers conducting the ERI study define exceptional responders as “patients who 
have dramatic and long-lasting responses to treatments for cancer that were not effective 
for most similar patients.” The precise definition of exceptional is specific to the disease, 
stage, and treatment.13–15 For GBM, defining what constitutes an exceptional response may 
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be more straightforward than for most cancers, since all primary GBM tumors are 
classified as grade IV and most patients receive the same standard treatment of tumor 
resection followed by radiation and chemotherapy with temozolomide. The response to 
this treatment is also very consistent, with most patients surviving very close to the 
median survival time and a relatively small number of patients surviving a substantially 
longer time.1–3  
 Due to the shortcomings in the methodology of defining survival groups in 
current GBM studies, there is a need for a GBM survival analysis utilizing cutoff 
parameters specific to characteristics of this disease. With the recent shift of focus to 
exceptional responders in cancer research, it is also important to incorporate this concept 
into survival studies in cancer, particularly in cancers like GBM, where most patients 
respond poorly to treatment but an exceptional few respond very positively. This study 
addresses both of these needs, utilizing an improved method of defining survival groups 
guided by the concept of exceptional responders. 
 
Methods 
 Inclusion criteria were applied utilizing clinical information contained within the 
TCGA Biotab files for GBM. Only untreated primary GBM samples from patients with 
known survival times were included in the survival analysis. A Kaplan-Meier survival 
curve was generated based on the survival times of the patients remaining after the 
application of the inclusion criteria. The top 10% of patients with the longest survival 
times were designated as “exceptional responders.” The 10% cutoff was chosen based on 
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the survival curve and loosely based on the ERI definitions of exceptional responders.15 
The median 10% of patients were classified as “typical responders” in order to have 
comparable sample sizes between the two groups. Linear regression models were 
generated with XLSTAT to investigate possible confounding variables that may influence 
survival, including sex, race, ethnicity, diagnosis method, age, and Karnofsky score. The 
term with the highest non-significant p-value was removed and the model was 
regenerated until the overall model and each term were significant (p < 0.05). An age 
cutoff was applied and linear regression models were generated again using the reduced 
number of samples in order to identify any remaining confounding variables. 
 
Results 
 After the application of the inclusion criteria, 408 patients remained in the dataset. 
The Kaplan-Meier survival curve (Figure 1) for those 408 patients shows a steep drop in 
the first two years, with the survival time for the vast majority of patients within one year 
of the median 345 days. The curve levels off between two and three years, and a relatively 
small number of patients survive beyond that time. The patients within that range are in 
roughly the top 10% for survival time, which was the defining factor for the exceptional 
responders group. 
 Age and sex were determined to be confounding variables in the linear regression 
models. An age cutoff of ≥30 years was applied, which reduced the exceptional responders 
group by five patients and corrected for the confounding variable of age. Ethnicity was 













Figure 1: Survival curve for TCGA GBM dataset. This curve includes the 408 TCGA GBM patients 
that met the inclusion criteria. The curve is characterized by a steep drop off centered around the 
median of 345 days, with a small number of patients surviving beyond approximately 2.5 years. 









race, and diagnosis method were not significant predictors of survival time. However, sex 
was predictive of outcome, with female patients enriched in the exceptional responders 
group (regression model p=0.021, chi-squared test p=0.034). Sex is only associated with 
survival in the typical and exceptional response groups, not in the full dataset of 408 
patients. 
 The final dataset included 40 typical responders and 35 exceptional responders 
(Table 2). Males are more highly represented in the typical response group, and the 
exceptional responders tend to be a bit younger with a mean age of 49.8 years compared 
to the typical responders’ mean age of 58.7 years. However, this age difference is not 
statistically significant. The median survival for the typical group is the same as the full 
dataset (345 days) with a range of 320-378 days. Median survival for the exceptional group 
is 1282 days (approximately 3.5 years) with a range of 864-3881 days (approximately 2.4-
10.6 years).  
 
Discussion 
 Although the current median survival time for GBM is approximately 15 months, 
the 12 month median in the full dataset and the typical responders group is consistent 
with the time period in which most of these samples were obtained.24 The characteristics 
of the survival curve are as expected based on previous GBM survival studies. 
 While the confounding variable of age was addressed with an age cutoff, the only 
way to fully address the confounding variable of sex is to completely exclude either males 











Table 2: Descriptive statistics for the full dataset and response groups. Statistics on sample size, 
age, and survival time are included for the full group of patients that met the inclusion criteria as 
well as for the typical and exceptional response groups. Typical responders closely resemble the 
norm for GBM in general, while exceptional responders tend to be younger (though this is not 
statistically significant) and have an equal representation of males and females as opposed to the 











restricting the relevance of this study to only one sex, this issue was addressed in each 
individual analysis for all data types, as described in subsequent chapters. 
 In order to ensure that no samples in the study had been exposed to radiation or 
other treatments that may corrupt results, only untreated tumor samples were included 
in the dataset. The dataset also includes only primary GBM samples in order to avoid 
statistical noise from secondary GBM samples, which develop through progression of 
low-grade astrocytomas and should be approached as a different disease.25 
 The typical and exceptional response groups defined in this chapter were utilized 




















 A variety of copy number variations have been identified in GBM, the most 
prevalent of which is amplification of chromosome 7, particularly of EGFR.26–28 Other 
frequently occurring copy number changes include losses of chromosomes 9p 
(particularly of CDKN2A, cyclin-dependent kinase inhibitor 2A)26,28,29 and 1026,27,29 as well 
as gains in chromosomes 19 and 2026,30. Some studies have associated these copy number 
alterations with prognosis, while others have determined that they are not significantly 
associated with outcome.27,30–32 
 Copy number alterations across the genome can be assessed with comparative 
genomic hybridization (CGH) arrays as well as single nucleotide polymorphism (SNP) 
genotyping arrays. The Affymetrix Genome-Wide Human SNP Array 6.0, which was the 
type of array utilized in this study, assesses more genetic variation than any other array. 




 Affymetrix Genome-Wide Human SNP Array 6.0 CEL files were obtained from 
the GDC Legacy Archive on April 15, 2017 for 38 typical and 34 exceptional responders 












 Typical Exceptional 
Female 11 17 
Male 27 17 
Table 3: Sample number by sex and response group in copy number analysis. Nearly all of the 
patients in the two response groups had copy number data available. As expected, there is a higher 
proportion of males in the typical response group and an equal number of males and female in the 










processed with the R tool Rawcopy.34 Log2 ratio values (relative to normal) obtained from 
the genelist files generated by Rawcopy were compared between typical and exceptional 
responders to identify any differential gains or losses. A log2 ratio cutoff of +/- 0.25 was 
used to define a copy number gain/loss, and only probes where the mean log2 ratio 
indicated a gain or loss for at least one of the response groups were included in the 
analysis. An additional cutoff was applied in which the difference in the mean log2 ratio 
between typical and exceptional responders must be > 0.2. Redundant probes (probes for 
the same gene with the same log2 ratio value) were removed. Welch’s unequal variances 
t-tests were performed for each remaining probe and a multiple testing correction was 
performed using the Benjamini-Hochberg false discovery rate (FDR) method (q < 0.1). This 
process was repeated for sex-specific analyses (typical male versus exceptional male and 
typical female versus exceptional female) with sex chromosomes excluded. A subset of 
results from this analysis were investigated with respect to the distribution of gains/losses 
and amplifications/deletions (log2 ratio cutoff +/- 0.8) between typical and exceptional 
responders. Significance was determined with chi-squared tests (p < 0.05) when the 
distributions of gains/amplifications and losses/deletions were compared. 
 
Results 
 Copy number heatmaps for each patient (Figure 2) show consistent alterations 
regardless of response group or sex. These include gains in chromosomes 7, 19, and 20 as 
well as losses in chromosomes 9p, 10, 13, and 14, all of which have been described 





Figure 2: Copy number heat maps by sex and response group. Heat maps generated by Rawcopy 
for typical and exceptional responders, separated by sex. For each response group, female patients 
are grouped above and male patients are grouped below. All groups are characterized by gains in 




response group (Figure 3) also indicates that those gains and losses occur consistently in 
both response groups, although the magnitude of the gain or loss typically appears to be 
greater in typical responders. 
 The Rawcopy analysis generates log2 ratios relative to normal for each probe in each 
array. After applying the cutoffs described above to the mean log2 ratios for each response 
group, 10 probes associated with alterations at 10 genes remained. Following the t-tests 
and multiple testing correction, 5 of these were determined to be differentially altered 
between the response groups (Table 4). The 5 genes identified are the olfactory receptors 
OR4M2 (p = 0.018) and OR4N4 (p = 0.022), as well as LOC285878 (p = 0.026), VSTM2A (p 
= 0.025), and CDKN2A-AS1 (p = 0.048). VSTM2A and LOC285878 were both characterized 
by gains, while OR4M2, OR4N4, and CDKN2A-AS1 were characterized by losses. The 
sex-specific analyses did not yield any significant results. 
 Utilizing a log2 ratio cutoff of +/-0.25 to define copy number gains/losses, several 
regions as well as specific genes were identified as altered relative to normal (Table 4). 
Most of these changes have already been implicated in GBM, and most of them were not 
significantly differentially altered between typical and exceptional responders. These 
included gains in chromosome 7p (Figure 4), losses in chromosome 9p (Figure 5), losses 
in chromosome 13q, and losses across the entirety of chromosome 10. Smaller regions of 
altered copy number included losses at LCE3C, ADAM3A, OR52N5, OR4M2, and OR4N4 
as well as gains at FKBP9, PRSS3P2, AND PRSS2. 
 Based on three of the genes identified as significantly differentially altered 











Figure 3: Genome-wide mean copy number for each response group.  Mean log2 ratios assessed 
at approximately 40,000 probes are shown in blue for typical responders and green for exceptional 
responders across the genome, excluding sex chromosomes. The most prominent alterations are 
gains in chromosome 7 and losses in chromosomes 9p and 10. Peaks tend to be of a greater 













Region and Gene(s) Response Group Affected 
7p11.2 
HPVC1, VSTM2A*, LOC285878*, SEC61G, 
EGFR, EFGR-AS1, LANCL2, VOPP1, FKBP9L, 
SEPT14, MRPS17, GBAS, PSPH, CCT6A, 
SNORA15, SUMF2, PHKG1, CHCHD2, and 
NUPR1L 
typical; exceptional to a lesser extent 
7q21.2 
AKAP9, CYP51A1, LRRD1, KRIT1, ANKIB1, 
GATAD1, PEX1, RBM48, MGC16142, 
FAM133B, and CDK6 
typical 
7q34 
PRSS3P2 and PRSS2 
typical 
Losses 








FOCAD, MIR491, PTPLAD, IFNB1, IFNW1, 
IFNA21, IFNA4, IFNA7, IFNA10, IFNA16, 
IFNA17, IFNA14, IFNA22P, IFNA5, KLHL9, 
IFNA6, IFNA13, IFNA8, IFNA1, MIR31HG, 
IFNE, MIR31, MTAP, CDKN2A-AS1*, 
CDKN2A, CDKN2B-AS1, CDKN2B, 
DMRTA1, FLJ35282, ELAVL2, IZUMO3, 
TUSC1, LOC100506422 
typical; exceptional to a lesser extent 









OR4M2* and OR4N4* 
exceptional 
Table 4: Regions of copy number gain and loss. Regions of copy number gain (mean log2 ratio > 
0.25) and loss (mean log2 ratio < -0.25 ) are shown with lists of specific genes affected in each region. 
The affected response group is described for each region. Genes in bold and labeled with a * 











Figure 4: Copy number gain in 7p11.2. Mean log2 ratios for typical (blue) and exceptional (green) 
responders in the region of chromosome 7p11.2 described in Table 3. Both groups are characterized 
by gains (log2 ratio > 0.25) and amplifications (log2 ratio > 0.8) in this region, but the magnitude is 
greater in typical responders. VSTM2A and VSTM2A-OT1 (marked with stars) have differential 
















Figure 5: Copy number loss in 9p21.2 and 9p21.3. Mean log2 ratios for typical (blue) and 
exceptional (green) responders in the region of chromosome 9p21 described in Table 3. Both groups 
are characterized by losses (log2 ratio < -0.25) in this region, but the magnitude is generally greater 
in typical responders. CDKN2A-AS1 (marked with a star) has differential copy numbers between 








found, EGFR and CDKN2A/B were investigated more closely due to their proximity to 
VSTM2A, LOC285878, and CDKN2A-AS1 as well as their previously established 
relevance to GBM.35 Chi-squared tests examining the distribution of gains/amplifications 
and losses/deletions among all patients in each response group indicate that typical 
responders are more likely than exceptional responders to experience loss or deletion of 
CDKN2A. The distributions of EGFR gain/amplification and CDKN2B loss/deletion were 
not significantly different between the response groups. 
 Of the 1812 probes that meet the definition of copy number gain/loss, 1752 of them 
are losses, and 1201 of those have a greater magnitude in typical responders. Only 60 
probes indicate copy number gains, and the magnitude is greater in typical responders 




Defining Cutoff Values 
 There is no standardized log2 ratio cutoff to define copy gain and loss or 
amplification and deletion. However, a cutoff of ±0.25 for gain/loss and ±0.8 for 
amplification/deletion is commonly utilized for copy number studies in cancer, which is 
why those definitions were applied in this study.36–38 
 The vast majority of log2 ratios in this study are between 0 and 1, making a fold 
change cutoff at worst misleading and at best uninformative. Rather than apply a fold 
change cutoff to identify regions of differential copy number alterations between the 
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response groups, a cutoff was applied in which the absolute value of the difference 
between the mean log2 ratios for typical and exceptional responders must be greater than 
0.2. This is the same value that is typically chosen for a Δβ cutoff in methylation studies, 
which also have values between 0 and 1.39–41  
 
Differentially Altered Genes Between the Response Groups 
 Two of the significantly differentially altered genes identified were olfactory 
receptors. This is likely an artifact and not actually associated with survival in GBM, 
because there is huge variation in copy number in the general population for 
approximately 50% of olfactory receptors.42 
 The other significant results include LOC285878 and VSTM2A, both of which are 
immediately upstream of EGFR, and CDKN2A-AS1, which overlaps slightly with 
CDKN2A and precedes CDKN2B. It is likely that these genes are significantly 
differentially altered between the response groups due to their very close proximity to 
EGFR and CDKN2A/B. Copy number alterations in GBM in both of those regions are very 
well characterized. It is for this reason that those genes were investigated further. Chi-
squared tests indicate that loss or deletion of CDKN2A is more likely to occur in typical 
responders than in exceptional responders, suggesting that copy number alteration of 






Other Gains and Losses 
 Several regions of copy number gain or loss relative to normal were identified in 
this analysis. Most of these met the definition of gain or loss for one response group and 
not the other, but did not reach statistical significance. Nevertheless, these may still be of 
clinical interest and are worth further exploration in larger studies in the future. Some of 
these alterations include loss of LCE3C, MIR16-1, MIR15A, and ST13P4 in exceptional 
responders, loss of ADAM3A in typical responders, and gain of PRSS2 in typical 
responders. Upregulation of MIR16 and MIR15a is associated with adverse prognosis and 
poor overall survival in multiple myeloma.43 Loss of these miRNAs in exceptional 
responders suggests reduced expression and lower tumorigenic potential in that response 
group. PRSS2 (protease, serine 2) is thought to play a role in tumor invasion in multiple 
cancers44–46 and may be contributing to more aggressive tumors in typical responders.  
 
Rates of Gains and Losses 
 Losses occurred much more frequently than gains in both response groups, and 
these alterations were consistently of a higher magnitude in typical responders (Figures 
3, 4, and 5; Table 4). This is consistent with previous studies showing that losses occur 
more frequently than gains in GBM, as well as cancers in general. This suggests that 
typical responders have more frequent or more severe copy number alterations, possibly 









Methylation and β Values 
 DNA methylation is an epigenetic mechanism in which a methyl group is added 
to a CpG site in the DNA. Methylation is typically associated with gene silencing, 
particularly when the CpG site is located within a promoter.47 The level of methylation at 
any given site is reported as a β value, which is the ratio of intensities between methylated 
and unmethylated alleles. This value ranges from 0 (unmethylated) and 1 (fully 
methylated). A β value greater than 0.7 is indicative of hypermethylation, while a β value 
under 0.3 is defined as hypomethylation.48–50 
 In glioblastoma, a recurrent methylation aberration occurs in the promoter for 
MGMT (O-6-methylguanine-DNA methyltransferase). Methylation in this region silences 
expression of MGMT, which leaves tumor cells susceptible to alkylating agents. 
Methylation of MGMT is therefore a marker of a positive response to chemotherapy 
treatment with temozolomide in GBM.51 
 
HumanMethylation27 Array 
 The HumanMethylation27 array utilizes Infinium genotyping technology to assess 
the methylation level at 27, 578 CpG sites covering 14,495 genes. This method begins with 
bisulfite conversion, which converts unmethylated cytosine into uracil and leaves 
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methylated cytosine alone. The DNA is then amplified, and uracil is matched with 
adenine, which then pairs with thymine for subsequent replications. The DNA is then 
hybridized to a chip, which has two probes for each locus (one for the methylated version 
and one for the unmethylated version). The different probes are then stained with 
different fluorescent agents and the level of methylation is determined with the 
calculation of β values.48,52 
 
Methods 
 Illumina HumanMethylation27 idat files were acquired from the GDC Legacy 
Archive on September 27, 2016 for 16 typical responders and 16 exceptional responders 
(Table 5). The analysis was performed with RnBeads, an R package designed to perform 
an analysis of DNA methylation at single nucleotide resolution in a more comprehensive 
manner than other methylation tools.53 The arrays were normalized with the beta-mixture 
quantile normalization method and the Greedycut algorithm was utilized for filtering. 
RnBeads includes a module that addresses batch effects. There was not an adequate 
number of samples to complete separate analyses to address the confounding variable of 
sex. Sex chromosomes were not included in the analysis to address this issue. The 
resulting lists of CpG sites and promoters were narrowed further with a Δβ (the absolute 
value of the difference between the mean β value for each response group) cutoff of 0.2, 
which is a commonly used cutoff for studies of differential methylation.39–41  The 
Benjamini-Hochberg multiple testing correction54 was performed (q < 0.1) to identify 











 Typical Exceptional 
Female 3 13 
Male 10 6 
Table 5: Sample number by sex and response group in methylation analysis. Nearly half of 
patients had methylation data available. The distribution of sex in this group does not follow the 
proportions of the full response groups, with nearly all of the typical responders being male and 
nearly all the exceptional responders female, rather than a slight male majority and an even split, 











2013 study on methylation in neuronal and glial cells in which Illumina 
HumanMethylation450 experiments were performed for non-neuronal cells of 6 different 
subjects, with 2 experiments for each subject.55 Mean β values were calculated from the 
signal intensities for all 12 sets. Kolmogorov-Smirnov (KS) tests were performed to 
compare the distributions of beta values for typical, exceptional, and normal groups. 
 
Results 
 The RnBeads report includes a differential methylation file comparing the mean 
degree of methylation between the typical and exceptional response groups at each of the 
approximately 27,000 CpG sites assessed by the Illumina assay. After applying the cutoffs 
and a multiple testing correction, 41 differentially methylated CpG sites corresponding to 
37 unique genes were identified (Table 6), 39 of which had a higher degree of methylation 
in the exceptional response group. A modified volcano plot (Figure 6) indicates which of 
these sites are outliers with the highest Δβ values and the lowest p values, with PCDHB12 
(protocadherin beta 12), LY6K (lymphocyte antigen 6 family member K), and NKX2-5 
(NK2 homeobox 5) among the top results. 
 The RnBeads report also includes a differential methylation file comparing the 
mean degree of methylation across promoter sites between the two response groups. In 
this case, data from multiple CpG sites in the same promoter (1.5 kb upstream and 0.5 kb 
downstream of the transcription start site) are combined to reflect the overall methylation 
level across the region. Utilizing the same cutoffs and multiple testing correction from the 
site analysis, 5 differentially methylated promoters, all with a higher degree of  
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cgid gene name mean β exceptional mean β typical Δβ p value 
cg12343638 PCDHB12 0.5078026 0.262902748 0.244899925 0.000792036 
cg08569678 LY6K 0.441856355 0.178005278 0.263851077 0.000901718 
cg12052765 CHAT 0.351379153 0.140280129 0.211099024 0.001210066 
cg03294619 NKX2-5 0.363597909 0.088957022 0.274640887 0.001724144 
cg21480743 PTEN 0.381009425 0.18046069 0.200548735 0.00232438 
cg04369341 C20orf100 0.63529373 0.426659616 0.208634114 0.002811554 
cg11532513 LRTM1 0.406058029 0.630219234 0.224161205 0.002811802 
cg17651821 HIST1H4L 0.513744205 0.256118974 0.257625231 0.003395508 
cg25957124 DNAH3 0.705059137 0.476860941 0.228198195 0.003418798 
cg01888566 MEST 0.74056681 0.521977296 0.218589514 0.003421299 
cg23519022 CAPZB 0.534783267 0.74339535 0.208612083 0.003806896 
cg24101578 CDH22 0.618165843 0.406560371 0.211605472 0.003809712 
cg25946389 MGMT 0.394523362 0.179592629 0.214930733 0.003829408 
cg25509184 CFTR 0.600842388 0.382027484 0.218814904 0.004066663 
cg09522147 KRT7 0.588742794 0.36717856 0.221564233 0.004232271 
cg10303487 DPYS 0.431869687 0.181799459 0.250070228 0.006518306 
cg09595479 PRPH 0.732006613 0.52721146 0.204795153 0.007883096 
cg18676237 SERPINB9 0.474358981 0.201989707 0.272369273 0.009013391 
cg12558519 KLHL26 0.34932085 0.099339316 0.249981535 0.009626013 
cg26980692 SLC15A3 0.401463369 0.190110148 0.211353221 0.010153909 
cg00949442 ABCA3 0.424217955 0.221278093 0.202939862 0.012334811 
cg24264506 TTC12 0.455964348 0.192059252 0.263905096 0.013005415 
cg16363586 BST2 0.679897957 0.474140835 0.205757122 0.01303555 
cg27090216 TNFRSF10C 0.323192125 0.115625389 0.207566736 0.013564396 
cg13067215 CGI-38 0.317780555 0.106700898 0.211079656 0.01374847 
cg20050826 K6IRS2 0.412443387 0.211270568 0.201172819 0.014985767 
cg21215336 LRRC8E 0.595433055 0.390559013 0.204874042 0.016306681 
cg12981137 MGMT 0.376274797 0.150035143 0.226239654 0.017000628 
cg01009664 TRH 0.460950967 0.249015311 0.211935657 0.018029927 
cg09160477 SUSD3 0.274926433 0.067484552 0.207441881 0.01810372 
cg07753583 LRRC61 0.62589652 0.417196705 0.208699815 0.01842675 
cg07952391 FLJ10916 0.409459146 0.184952884 0.224506262 0.018626547 
cg23244913 HCG9 0.543443874 0.332649804 0.21079407 0.018700098 
cg12177743 TTC12 0.331577699 0.116007362 0.215570337 0.019122814 
cg06274159 ZFP42 0.630768539 0.422974537 0.207794002 0.019292771 
cg25057743 PTHR2 0.385272981 0.183412711 0.201860269 0.022032263 
cg07260592 LPA 0.653635527 0.435082623 0.218552904 0.022092278 
cg17965019 HIST1H3J 0.352617133 0.142842183 0.20977495 0.024151396 
cg17860158 CNTN2 0.394115837 0.183061088 0.21105475 0.025666055 
cg12768605 LYPD5 0.498629758 0.298008361 0.200621398 0.033938924 
cg00630164 KCNQ4 0.489497043 0.277459749 0.212037294 0.042287698 
Table 6: Significantly differentially methylated CpG sites. These 41 CpG sites were determined 
to be differentially methylated between typical and exceptional responders following a Δβ cutoff 











Figure 6: Modified volcano plot of significantly differentially methylated CpG sites. This 
includes the 41 CpG sites listed in Table 5. Each axis is skewed to reflect the cutoffs made to assess 
significance (p < 0.05 and Δβ > 0.2). Sites with a lower degree of methylation in typical responders 
are shown in blue and sites with a lower degree of methylation in exceptional responders are 
shown in green. Sites in the upper right hand side have the largest Δβ values and the smallest p 








methylation in exceptional responders, were identified (Table 7). These include SLC15A3 
(solute carrier family 15 member 3), TTC12 (tetratricopeptide repeat domain 12), LRRC8E 
(leucine rich repeat containing 8 family member E), SUSD3 (sushi domain containing 3), 
and LRRC61 (leucine rich repeat containing 61). 
 There are 45 CpG sites with a Δβ value greater than 0.2 between the typical and 
exceptional response groups, 41 of which are also present in the normal dataset. 
Histograms for each of these groups (Figure 7) show larger proportions of 
hypomethylated (β < 0.3) sites in the typical and normal groups and more moderate β 
values in the exceptional group. This observation was investigated further with KS tests 
and cumulative distributions plots for each group (Figure 8). There is no difference in the 
distribution of β values between typical responders and normal glial cells (p=0.127), but 
the exceptional response group β value distribution is significantly different from both of 
the other groups (p<0.0001 in both cases). The D statistic (a measure of the magnitude of 
the difference between two datasets) is 0.622 for the typical versus exceptional comparison 
and 0.734 for the normal versus exceptional comparison.  
 
Discussion 
Addressing the Confounding Variable 
 The distribution of sex between the typical and exceptional response groups is 
quite skewed in the methylation dataset. For the other data types in this study, analyses 
were typically performed three times: once for typical versus exceptional responders 











gene name mean β exceptional mean β typical Δβ combined p value 
SLC15A3 0.401463369 0.190110148 0.211353221 0.010153909 
TTC12 0.393771023 0.154033307 0.239737716 0.01224649 
LRRC8E 0.595433055 0.390559013 0.204874042 0.016306681 
SUSD3 0.274926433 0.067484552 0.207441881 0.01810372 
LRRC61 0.62589652 0.417196705 0.208699815 0.01842675 
Table 7: Significantly differentially methylated promoters. The promoters of these five genes 
were determined to be differentially methylated between typical and exceptional responders 
following a Δβ cutoff of 0.2 and multiple testing correction (q < 0.1), based on the degree of 
methylation of all the CpG sites that fall within the promoter range (1.5 kb upstream and 0.5 kb 



















Figure 7: Histograms of β values in normal glial cells and each response group. The response 
group histograms include mean β values for the 45 CpG sites with Δβ values larger than 0.2, and 
the normal histogram includes β for 41 of those sites (the remaining 4 were not assessed in the 
normal arrays). The distribution of β values in typical responders closely resembles the normal 















Figure 8: KS tests and cumulative distribution plots of β values. KS tests indicate that the 
distribution of β values for the CpG sites with Δβ > 0.2 is significantly different from both the 
typical and normal distributions (p < 0.0001). There is no difference between the distributions for 
the typical and normal groups. Cumulative distribution plots are shown for each of the three 
groups, indicating a clear shift in exceptional responders toward higher β values. The D statistic, a 
measure of the magnitude of the difference between two datasets, is shown for each comparison 
at the point of greatest difference. The distance between the exceptional and normal distributions 






In the case of methylation, this was not possible due to an insufficient number of samples. 
Instead, sex chromosomes were removed from the analysis in an effort to control for 
methylation differences between sexes. When this step was not taken, 44% of significant 
sites and 57% of significant promoters were on the X chromosome, which was likely due 
to X-inactivation and the large difference in the number of female patients between the 
response groups. This method seems to have been effective as many of the results are 
associated with GBM specifically or with other cancers and are often prognostic factors. 
 
Determination of an Appropriate Δβ Cutoff 
 A log2 fold change cutoff is not appropriate for comparing β values since they are 
all between 0 and 1 and very large fold change values could result from very small 
changes in beta values, and vice versa. Instead, a Δβ cutoff was applied. A cutoff value of 
0.2 was selected based on the literature and on the 27k assay technology. Most methylation 
studies that use Δβ values select 0.2 as the cutoff39–41, and the Infinium I technology used 
in the HumanMethylation27 arrays can detect a Δβ of approximately |0.2| with 99% 
confidence.56   
 
Differentially Methylated Regions 
 Although there are many genes implicated in the site-specific analysis that did not 
appear in the results of the promoter analysis, this does not necessarily indicate that the 
site-specific results are not important. There are many more CpG sites than the 27k 
technology assesses, so it is entirely plausible that the promoters for those genes have 
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more sites that are differentially methylated between the response groups that simply 
were not interrogated with the 27k arrays. A similar study with data from the Illumina 
450k or EPIC (which assesses methylation status at over 850,000 CpG sites) platform 
would be a significant improvement. Unfortunately, there was not a sufficient number of 
patients that had 450k results to perform such an analysis. 
 As expected, MGMT was present in the results and is characterized by a higher 
level of methylation in exceptional responders. Several other genes present in the top 
results with a higher degree of methylation in exceptional responders are associated with 
cancer prognosis and/or treatment response, including LY6K (lymphocyte antigen 6 
family member K)57,58, DPYS (dihydropyrimidinase)59, and SERPINB9 (serpin family B 
member 9)60,61. The reduced methylation of those genes in typical responders suggests 
increased transcription, and expression of each of those genes is associated with more 
aggressive tumors in various cancers.  
 Only two of the significantly differentially methylated sites had a higher level of 
methylation in typical responders. Those two sites are associated with the genes CAPZB 
(capping actin protein of muscle Z-line beta subunit) and LRTM1 (leucine rich repeats and 
transmembrane domains 1). LRTM1 is not well-characterized, but CAPZB is known to be 
an actin-capping protein that plays a role in cell morphology and differentiation. CAPZB 
is a metastasis-suppressor in hepatocellular carcinoma62 and its lower methylation levels 
in exceptional responders suggest that it may be more highly expressed than it is in typical 




Differential β Value Distribution 
 Among CpG sites that have a Δβ greater than 0.2, the typical group closely 
resembles the normal beta value distribution, while the exceptional group is characterized 
by a higher level of methylation. Nearly all (95%) of the differentially methylated CpG 
sites and 100% of the differentially methylated promoters have a higher degree of 
methylation in exceptional responders. Histograms and cumulative distribution plots 
show a strong shift towards higher β values in exceptional responders, and the KS tests 
indicate that this difference is statistically significant. This hypermethylation in 
exceptional responders relative to typical responders and normal glial cells suggests an 



















Gene Expression Microarrays 
 Gene expression levels can be assessed with multiple methods, but the gene 
expression data in this study was generated with Affymetrix microarrays. This technology 
enables the analysis of gene expression across the whole genome, including more than 




 Guanine Cytosine Robust Multi-Array Analysis (GCRMA) is a Bioconductor 
package that performs normalization of microarrays. This tool implements a background 
correction, followed by a normalization step to make measurements between different 
arrays comparable, and then a summarization step to calculate a final expression 
measurement. It also adjusts for background intensities including optical noise and non-
specific binding. It is an improvement upon the commonly used Robust Multi-Array 
Analysis (RMA) algorithm, which does not adjust well for non-specific binding.64,65 
 Another tool utilized in this analysis is nsFilter, which is part of the genefilter 
package and removes non-informative genes to reduce noise in the analysis. This tool 
removes genes with little variation, consistently low signals, and control probe sets.66 
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 Limma is a software package for the analysis of gene expression. It utilizes linear 
models to assess differential expression for a variety of technologies, including 
microarrays, RNA sequencing, and quantitative PCR.67–69 
 
Aberrant Gene Expression in GBM 
 The most well-known and most frequently occurring gene expression change in 
GBM is the overexpression of EGFR. Other hallmark genes in GBM include IGFBP2 
(insulin like growth factor binding protein 2), IGFBP5 (insulin like growth factor binding 
protein 5), VEGF (vascular endothelial growth factor), VCAM1 (vascular cell adhesion 




 Affymetrix HT Human Genome U133 DNA microarray CEL files were obtained 
from the GDC Legacy Archive on August 5, 2016 for 33 exceptional responders and 34 
typical responders (Table 8). Three comparisons were performed: all exceptional 
responders vs all typical responders, male exceptional responders vs male typical 
responders, and female exceptional responders vs female typical responders. For each of 
the three analyses, the arrays were normalized with GCRMA and filtering was performed 
using the nsFilter function of the genefilter package in R. All experiments were performed 
at the same location, which should minimize batch effects. Quality control tests, including 











 Typical Exceptional 
Female 11 17 
Male 23 16 
Table 8: Sample number by sex and response group in gene expression analysis. Most patients 
in both response groups had gene expression data available. The distribution of sexes between the 
two groups is consistent with the full groups, with a male majority in the typical group and a 













before and after normalization. Differential expression analysis was performed using 
limma. A log2 fold change cutoff of 1.5 was applied to the resulting list of probes before 
the multiple testing correction was performed. Only genes that were implicated in all 
three analyses or in the full analysis but not in the sex-specific analyses were considered 
to be significantly differentially expressed between the two response groups. Linear 
regression models were generated with XLSTAT to investigate the prognostic value of 
some of the differentially expressed genes. These models were generated using the full 
TCGA GBM dataset, including 385 patients. Utilizing the same CEL files that were 
analyzed with limma, version 2.2.4 of the Broad Institute’s Gene Set Enrichment Analysis 
(GSEA) tool was used to detect enrichment of gene sets between exceptional and typical 
responders as well as male and female patients. The CEL files were converted to Gene 
Count files using the ExpressionFileCreator module found in GenePattern. Normalization 
was performed with GCRMA in conjunction with quantile normalization. GSEA was run 




 Quality control assessments indicate that all arrays included in the analysis were 
normalized properly and none need to be excluded. Box plots of the log intensity 
distributions for each array (Figure 9) are extremely consistent following normalization, 
indicating that between-array comparisons can be made with this dataset without 








Figure 9: Quality control assessment by log intensity distributions. Log intensity distributions 
were generated in R before normalization (top) and after normalization (bottom) to determine if 
between-array comparisons could be made or if any arrays needed to be removed. The consistent 
distributions following normalization indicate that all arrays in the analysis could be compared 










Figure 10: Quality control assessment by density plot. Density plots of log intensity distribution 
were generated in R before normalization (top) and after normalization (bottom) to identify any 
arrays with an abnormal distribution. Following normalization, all the arrays had consistent log 








consistent distributions following normalization, meaning that there are no outliers that 
need to be excluded. 
 The analysis identified 4 significantly differentially expressed genes (Table 9). 
ETNPPL (ethanolamine-phosphate phospho-lyase) and SH3GL2 (SH3 domain containing 
GRB2 like 2, endophilin A1) were more highly expressed in exceptional responders, while 
CXCL8 (interleukin 8) and CCL20 (chemokine ligand 20) were more highly expressed in 
typical responders. There were 13 additional genes determined to be significantly 
differentially expressed in the full analysis, but they were all also identified in one sex-
specific analysis and not the other. These were excluded from the final results because 
they may only be present due to sex being a confounding variable. 
 Linear regression models indicate that CXCL8 is predictive of survival time. 
Increased expression of CXCL8 is associated with reduced survival time. The overall 
model is statistically significant (p < 0.001), as is the CXCL8 term (p < 0.001). The equation 
for the model is: 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑡𝑖𝑚𝑒 (𝑑𝑎𝑦𝑠) = 812 − 40.1 ∗ 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 𝑜𝑓 𝐶𝑋𝐶𝐿8. 
 GSEA identified 4 gene sets enriched in exceptional responders and 1 gene set 
enriched in typical responders (Table 10). The leading edge analysis revealed which genes 
contributed to the enrichment of which gene sets in the exceptional responders (Figure 
11). NLGN1 and STXBP1 contributed to the enrichment of all four gene sets and RAB3A, 
RIMS3, SNCA, SYN1, RAB5A, RAB3GAP1, and PFN2 contributed to the enrichment of 
three of them. All of the other implicated genes were associated with only one or two of 
the gene sets. There were no significantly enriched gene sets identified when the analysis 























ETNPPL 1.553 1.931 1.659 0.0225 0.0703 0.0560 












CCL20 -1.751 -2.383 -1.520 0.0042 0.0155 0.0487 
Table 9: Significantly differentially expressed genes. Four genes were determined to be 
significantly differentially expressed between typical and exceptional responders following 
multiple testing correction (q < 0.1) and comparison to the sex-specific analyses. Log2 fold change 
(log2FC) and p values are shown for the full analysis and for each sex-specific analysis. ETNPPL 
and SH3GL2 are more highly expressed in exceptional responders and CXCL8 and CCL20 are more 



















p value FDR q value 
regulation of synaptic vesicle 
transport 
exceptional 2.062 p < 0.001 0.124 
regulation of neurotransmitter 
transport 
exceptional 2.025 p < 0.001 0.113 
positive regulation of calcium 
ion dependent exocytosis 
exceptional 2.008 p < 0.001 0.109 
neurotransmitter secretion exceptional 2.006 p < 0.001 0.078 
negative regulation of 
cytokine biosynthetic process 
typical -2.068 p < 0.001 0.154 
Table 10: Enriched gene sets identified by GSEA. GSEA identified five enriched gene sets, four 











Figure 11: Leading edge analysis of gene sets enriched in exceptional responders. Leading edge 
analysis of the four gene sets enriched in exceptional responders indicated which genes contributed 
to each result. The color gradient indicates the range of expression values (red, pink, light blue, and 
dark blue correspond to high, moderate, low, and lowest expression, respectively). Two genes 
contributed to all four results and seven genes contributed to three of the four, but most of the 





Addressing the Confounding Variable 
 A majority of the genes identified as being significantly differentially expressed in 
the full dataset were excluded because they were also present in the results of only one of 
the sex-specific analyses and may only appear to be significant due to the confounding  
variable of sex. In several of the cases, at least, this seems very likely. Some of the genes 
excluded for potentially being the result of differential expression between males and 
female include XIST, RPS4Y1, and DDX3Y. XIST is expressed in females as the major 
effector of the X inactivation process, and RPS4Y1 and DDX3Y are both found on the Y 
chromosome and should therefore only be expressed in males. That these were excluded 
from the final results by the methodology for this analysis suggests that this method was 
successful in controlling for sex-specific results. 
 
Significantly Differentially Expressed Genes 
 The four genes included in the final results list are CXCL8, CCL20, ETNPPL, and 
SH3GL2. CXCL8 is an angiogenic factor in GBM, gliomas, and many other cancers and 
CCL20 promotes malignancy in various cancers and has been implicated in glioma.71–77 
Both of those genes were overexpressed in typical responders relative to exceptional. 
CXCL8 and CCL20 are often implicated in diseases together, particularly in colorectal 
cancer, in which they synergize to promote a poor survival outcome via a collaborative 
induction of the epithelial-mesenchymal transition.78 Overexpression of these two genes 
are likely contributing to the poorer prognosis of typical responders. In vivo studies of 
49 
 
overexpression of these genes in GBM cell lines would be necessary to confirm that they 
contribute to a more tumorigenic phenotype. 
 The other two significant genes were more highly expressed in exceptional 
responders. ETNPPL is a lyase that is downregulated in hepatocellular carcinoma, and 
SH3GL2 is a positive prognostic factor in head and neck squamous cell carcinoma.79 
SH3GL2 is targeted by mir330, which promotes malignancy in GBM cell lines, suggesting 
that reduced expression of SH3GL2 results in more aggressive tumors.80 The 
overexpression of these two genes is consistent with a more positive prognosis. 
 
CXCL8 is Predictive of Survival Time 
 Based on the established relationship between CCL20 and CXCL8 in the literature, 
these two genes were investigated as possible prognostic factors for GBM with linear 
regression models. While the term for CCL20 was not statistically significant in the model, 
when it was removed and the model was regenerated with CXCL8 only, it was found to 
be significantly predictive of survival. The equation for the model suggests that for every 
one unit increase in CXCL8 expression, there is an associated 40 day reduction in survival. 
CXCL8 is a chemokine and potent angiogenic factor that may contribute to 
tumorigenesis81, so its overexpression in typical responders relative to exceptional 
responders is indicative of more aggressive tumors in typical responders, which may 
explain the significant association between higher CXCL8 expression and shorter survival 





 GSEA identified 5 enriched gene sets, 4 of which were enriched in exceptional 
responders and 1 of which was enriched in typical responders. The four gene sets enriched 
in exceptional responders are all very similar and are related to synaptic transmission, 
suggesting that exceptional responders have an increased ability to maintain synaptic 
transmission functions and that it might be granting them some advantage over typical 
responders. 
 Interestingly, 6 of the genes contributing to the enriched gene sets in exceptional 
responders (STXBP1, DNM1, SYNJ1, KCNB1, PLCB1, and CACNA1A) are among a group 
of genes that have been implicated in early infantile epileptic encephalopathy (EIEE)82, an 
extremely debilitating disorder characterized by uncontrollable seizures and severe 
mental retardation.83 Mutations in these genes are associated with EIEE, but it appears 
that overexpression of these genes is associated with a positive prognosis in GBM. All of 















 Micro RNAs (miRNAs) are a class of regulatory molecules that have been 
implicated as important players in tumorigenesis.84 A subset of miRNAs have been found 
to be consistently dysregulated in GBM (Table 11) and some of these can also be used to 
predict prognosis or therapeutic response. Aberrant expression of these miRNAs can 
impact tumorigenic pathways in GBM such as induction of angiogenesis, resistance to 
apoptosis, and sustained proliferation signaling.85 
 The miRNA expression data for this study were generated with the Agilent 
Human miRNA Microarray 8x15K platform. These microarrays contain probes with high 




 Files containing the calculated expression values of 534 miRNAs for 38 typical and 
34 exceptional responders (Table 12) were retrieved from the GDC Legacy Archive on 
September 1, 2016. Welch’s unequal variances t-tests were performed for each miRNA to 
identify which ones are significantly differentially expressed between the response 











miR-9 miR-10a miR-10b miR-15b miR-17-5p 
miR-25 miR-21 miR-26a miR-92b miR-93 
miR-106a miR-130a miR-155 miR-182 miR-196b 
miR-210 miR-221 miR-222 miR-296 miR-451 
Downregulated 
miR-7 miR-34a miR-124* miR-125b miR-128* 
miR-129-5p* miR-132 miR-136 miR-137 miR-139-5p* 
miR-146b miR-153 miR-181* miR-184 miR-218 
miR-323 miR-326 miR-328 miR-495  
Table 11: Consistently dysregulated miRNAs in glioblastoma. These miRNAs have been 
established as frequently upregulated or downregulated in GBM85 and were used as a guide to 
reduce multiple testing in the analysis. miRNAs labeled with a * were not assessed by the arrays 




















 Typical Exceptional 
Female 11 17 
Male 27 17 
Table 12: Sample number by sex and response group in miRNA analysis. Nearly all of the 
patients in both response groups had miRNA expression data available. The distribution of sexes 
in the two groups is similar to the full groups, with most a majority of typical responders being 














FDR method (q < 0.1). The t-tests and corrections were performed again on a reduced 
dataset after the miRNA list was restricted to only those miRNAs that appear in Table 11. 
 
Results 
 No miRNAs were significantly differentially expressed between typical and 
exceptional responders following the multiple testing correction, even when multiple 
testing was reduced by restricting the results to only miRNAs known to be consistently 
dysregulated in GBM. Prior to correcting for multiple testing, there were 37 miRNAs with 
p < 0.05 in the full dataset and 2 in the reduced dataset (Table 13). 
 
Discussion 
 Although quite a few miRNAs have been associated with GBM, including some 
that are specifically associated with prognosis or treatment response85, no significantly 
differentially expressed miRNAs were identified in this study. This does not necessarily 
mean that the miRNAs analyzed are not important in GBM. They may be differentially 
expressed in both response groups relative to normal expression, but simply not be 
differentially expressed between the response groups themselves. 
 Several of the top results have previously been associated with GBM prognosis or 
with prognosis and/or treatment response in other cancers. However, these results did 
not reach statistical significance after a multiple testing correction was applied, so they 










































Table 13: Differentially expressed miRNAs. This includes the top results of the miRNA analysis 
(all miRNAs with p < 0.05). miRNAs labeled with a * also appeared in the reduced analysis based 
on the list in Table 10. None of these results reached statistical significance following a multiple 








 Reverse Phase Protein Array (RPPA) is a high throughput assay in which 
antibodies are printed across slides to quantify the amounts of various proteins in 
multiple samples simultaneously. This method allows for sensitive and accurate 
quantification of proteins, including phosphoproteins, from a small amount of sample 
material as long as high quality antibodies are available. The TCGA protein expression 
data is generated by the MD Anderson RPPA Core Facility, which currently utilizes a 
panel of 304 antibodies in its experimental protocol.87,88 The GBM dataset includes results 
for 222 antibodies. 
 
Methods 
 Files containing relative protein expression data were obtained from the GDC 
Legacy Archive for 7 typical and 13 exceptional responders (Table 14) on September 24, 
2016. Mann-Whitney U tests were performed for each of the 222 antibodies to identify 
which proteins are significantly differentially expressed between the response groups. 
The multiple testing correction was performed using the Benjamini-Hochberg FDR 














 Typical Exceptional 
Female 2 6 
Male 5 7 
Table 14: Sample number by sex and response group in protein expression analysis. Very few 
patients had protein expression data available. The sex distribution across response groups was 













 No proteins were significantly differentially expressed between typical and 
exceptional responders following the multiple testing correction. Without correcting for 
multiple testing, there are five proteins with significant p values (p < 0.05). These proteins 
are associated with the genes ITGA2, BCL2, BCL2A1, RPS6KB1, and RAD51 (Table 15). 
 
Discussion 
 Unlike most of the other data types investigated in this work, the protein 
expression arrays assess a relatively small number of data points. While most of the other 
analyses were genome-wide, the protein expression data type includes results for just 222 
antibodies.  Being limited to this comparatively small panel substantially diminishes the 
likelihood of identifying differential aberrations between typical and exceptional 
responders for this data type, which may be part of the reason why no statistically 
significant results were identified. 
 The protein expression analysis was also characterized by a much smaller sample 
size than most of the other analyses, with only 7 typical and 13 exceptional responders. 
Perhaps with a larger sample size, there would be more definitive and statistically 
significant results. 
 Of the top results, both BCL2 (B-cell lymphoma 2) and RAD51 (RAD51 
recombinase) have been associated with GBM prognosis.89,90 However, because these 
results did not reach statistical significance following the multiple testing correction, they 










Antibody Gene p value 
CD49b-M-V ITGA2 0.0027 
Bcl-2-M-V BCL2 0.0198 
Bcl2A1-R-V BCL2A1 0.0252 
P70S6K-R-V RPS6KB1 0.0324 
RAD51-M-C RAD51 0.0329 
Table 15: Differentially expressed proteins. This includes the top results of the protein expression 
analysis (all antibodies with p < 0.05). The gene associated with the protein that each antibody 
labels is listed. None of these results reached statistical significance following a multiple testing 













INTEGRATION AND PATHWAY ANALYSES 
 
Introduction 
 Pathway analysis techniques are used to help interpret the results of omics studies 
by identifying genes that play a role in the same cellular process, disease, signaling 
pathway, or other biological pathway. This can provide a global perspective on the results 
generated and can help with understanding the results in terms of biological relevance.91 
Two commonly utilized pathway analysis tools are Gene Ontology (GO)92 and the Kyoto 
Encyclopedia of Genes and Genomes (KEGG).93 
 The GO project is a tool used to describe gene products in terms of gene product 
properties, including molecular functions and associated biological processes.92 ClueGO is 
a Cytoscape plug-in that utilizes Cytoscape’s visualization capabilities to generate a GO 
term network. This tool includes a Fusion feature to reduce redundancy by combining 
related GO terms into the most representative term.94  
 KEGG is a comprehensive database that represents the current knowledge of 
molecular interaction and reaction networks and is usually utilized to understand 
biological pathways and systems, especially in large-scale genomic datasets. This resource 
can be used to derive a systems-level understanding of molecular-level information and 






 In order to integrate the results from the individual analyses of this study and 
derive some functional significance, genes contributing to enriched gene sets, 
differentially expressed or methylated genes, and genes with differential copy number 
gains/losses (Table 16) were combined and used as the input for GO and KEGG analyses 
for each response group. The GO analysis was performed using the Cytoscape plug-in 
ClueGO with all four GO types selected, GO Term Fusion enabled, and results restricted 
to pathways with p<0.05 after Benjamini-Hochberg FDR multiple testing correction. All 
other parameters were left as the default. In the KEGG analysis, only pathways with at 
least 3 associated genes were included for further consideration. Heat maps were 
generated with Heatmapper. Both Pearson (r) and Spearman (ρ) correlation coefficients 
were calculated to assess the degree and direction of correlation between gene expression 
and copy number as well as gene expression and methylation. 
 
Results 
 Three enriched GO terms were identified from the gene list that is upregulated in 
typical responders (Table 17). These include regulation of lipid storage, regulation of 
interleukin-10 production, and regulation of cytokine biosynthetic process. The 
exceptional responders, however, had 105 enriched GO terms which ClueGO GO Term 
Fusion reduced to 12 enriched GO terms (Table 18 and Figure 12). Almost all of the 





 Typical Responders Exceptional Responders 







































































Table 16: Significantly upregulated genes across all analyses. Genes with statistically significant 
alterations between the two response groups are included. “Upregulated” for each data type is 
defined as follows: copy number gains, lower promoter methylation, increased gene expression, 
and enrichment in GSEA. The only significant results not included are differentially methylated 
CpG sites. Only promoters were included from the methylation results because promoter 
methylation is consistently negatively correlated with gene expression, while methylation of sites 













GO Term p value Associated Genes 
regulation of cytokine 
biosynthetic process 
1.50x10-22 
BCL3, CCL20, IL6, INHBA, INHBB, KLF4, 
LAG3, NFKB1, NMI, RNF128, SFTPD, TRIB2 
regulation of interleukin-10 
production 
1.50x10-05 BCL3, IL6, TRIB2 
regulation of lipid storage 1.90x10-05 IL6, NFKB1, VSTM2A 
Table 17: Significantly enriched GO terms in typical responders. Three GO terms were identified 
as significantly enriched in typical responders following Benjamini-Hochberg FDR multiple testing 
correction. The p values are adjusted. Each group identified with GO Term Fusion only has one 













GO Term p value Associated Genes 
presynaptic process 
involved in chemical 
synaptic transmission 
2.9x10-31 
ASIC1, CACNA1A, CAMK2A, CDK5, 
KCNMB4, MEF2C, NF1, NLGN1, PFN2, 
RAB3A, RAB3GAP1, RAB5A, RIMS1, RIMS3, 
SNCA, SNCAIP, SNCG, STXBP1, SYN1, SYNJ1, 




ASIC1, CACNA1A, CAMK2A, KCNMB4, 
MEF2C, NF1, NLGN1, NOS1, PFN2, RAB3A, 
RAB3GAP1, RAB5A, RIMS1, RIMS3, SNCA, 
SNCAIP, SNCG, STXBP1, SYN1, SYT11, TOR1A 
synaptic vesicle exocytosis 4.9x10-27 
CACNA1A, CDK5, NLGN1, PFN2, RAB3A, 
RAB3GAP1, RAB5A, RIMS1, RIMS3, STXBP1, 
SYN1, SYNJ1, SYT1, SYT11 
regulation of synaptic 
vesicle recycling 
3.0x10-24 CDK5, DNM1, NLGN1, SNCA, SYT11, TOR1A 
regulation of synaptic 
vesicle exocytosis 
6.1x10-22 
NLGN1, PFN2, RAB3A, RAB3GAP1, RAB5A, 




CACNA1A, CDK5, DNM1, MEF2C, NF1, 
NLGN1, PINK1, RAB3GAP1, SNCA, STXBP1, 
SYT1, TOR1A 
regulation of synaptic 
plasticity 
1.2x10-15 
CAMK2A, CDK5, KCNB1, MEF2C, NF1, 
NLGN1, RAB3A, RAB3GAP1, SNCA, STXBP1, 
SYT11 
acid secretion 1.5x10-15 
CACNA1A, NF1, RAB3A, RAB3GAP1, RIMS1, 
SNCA, STXBP1, SYT1 
positive regulation of 
synaptic transmission 
2.1x10-15 
NF1, NLGN1, PINK1, RAB3GAP1, RIMS1, 
SNCA, SYT1, SYT11 
regulation of amine 
transport 
6.8x10-13 
CACNA1A, KCNB1, PINK1, RAB3GAP1, 
SNCA, SNCG, SYT1, TOR1A 
positive regulation of 
protein targeting to 
membrane 
2.3x10-5 CACNA1A, CDK5, KCNB1 
voltage-gated calcium 
channel complex 
5.0x10-5 CACNA1A, CACNA1I, NOS1 
Table 18: Significantly enriched GO terms in exceptional responders. Twelve GO term groups 
were identified as significantly enriched in exceptional responders following Benjamini-Hochberg 
FDR multiple testing correction. The p values are adjusted and based on the groups identified by 













Figure 12: GO Term Fusion results in exceptional responders. The 12 GO term groups identified 
with GO Term Fusion are associated with 105 enriched GO terms. The pie graph indicates the 










 KEGG analysis for the typical responders identified quite a few pathways based 
on 5 subsets of the upregulated genes (Table 19). The top results are the IL-17 signaling 
pathway and the TNF signaling pathway. The KEGG analysis for the exceptional 
responders gene list yielded 5 enriched pathways, including synaptic vesicle cycle, MAPK 
signaling pathway, calcium signaling pathway, Alzheimer’s disease, and Parkinson’s 
disease (Table 20). 
 The relationships between the data types with significant results (copy number, 
methylation, and gene expression) was further investigated with heat maps and 
correlation analyses (Figure 13 and Table 21). Among only the genes identified in Table 
16, there is a weak to moderate positive correlation between copy number and gene 
expression for both response groups, with similar coefficients resulting from both the 
Pearson and Spearman tests. A strong negative correlation between methylation and gene 
expression was indicated by both correlation tests for that same gene list. When 
comparing methylation and gene expression genome-wide, there is a moderate to strong 
negative correlation for both the typical responders (r = -0.356, ρ = -0.363) and the 
exceptional responders (r = -0.365, ρ = -0.387). 
 
Discussion 
Spearman versus Pearson Correlation 
 Both the Spearman and the Pearson correlation methods are utilized in the 
literature to assess the relationship between methylation and gene expression, but most 






















 Pathways in cancer 






Kaposi’s sarcoma-associated herpesvirus infection 
Transcriptional misregulation in cancer 
Toll-like receptor signaling pathway 
Cellular senescence 
Hepatitis B 
NOD-like receptor signaling pathway 












Chemokine signaling pathway 
Table 19: Significantly enriched KEGG pathways in typical responders. KEGG analysis 









































Table 20: Significantly enriched KEGG pathways in exceptional responders.  KEGG analysis 












Figure 13: Heat maps for methylation and gene expression. Heat maps were generated with all 
genes from Table 15 that had data for both methylation and gene expression. Heat maps for both 
typical and exceptional responders indicate a negative correlation between methylation and gene 












 Copy Number & Gene Expression Methylation & Gene Expression 
Pearson (r) 0.2333 -0.4484 
Spearman (ρ) 0.2496 -0.5174 
Exceptional 
 Copy Number & Gene Expression Methylation & Gene Expression 
Pearson (r) 0.2120 -0.6065 
Spearman (ρ) 0.2370 -0.5857 
Table 21: Correlation between copy number/methylation and gene expression. Each correlation 
test was performed for the list of genes in Table 15, excluding those that did not have data available 
for the relevant data type. The results indicate a weak to moderate positive correlation between 









variables, while the Spearman test is more suited to categorical variables.95 β values are a 
continuous variable, so the Pearson test seems more appropriate, but the Spearman test 
generally gives results of a larger magnitude for correlations between methylation and 
gene expression, which is perhaps why it is used so often for those types of studies. It is 
possible that the Spearman test typically gives better results because methylation may be 
more categorical than continuous in reality, functioning more like an on/off switch than 
in a linear manner. In any case, both tests were utilized in this study to provide a clearer 
understanding of the relationship between methylation and gene expression for this 
dataset. 
 
Enriched GO Terms 
 The main contributors to the enriched GO terms for typical responders are IL6 
(interleukin 6), which is associated with all three terms, and BCL3 (B-cell lymphoma 3), 
NFKB1 (nuclear factor kappa B subunit 1), and TRIB2 (tribbles pseudokinase 2), which are 
associated with two terms each. All four of these genes are associated with NF-κB, a 
protein complex that acts as a transcription factor and plays a role in cytokine production 
and cell survival. NF-κB is constitutively active in many cancers, causing cells to 
proliferate and protecting them from death by apoptosis.96 Activation of NF-κB in GBM 
has been shown to contribute to angiogenesis and temozolomide resistance.97 Typical 
responders are characterized by a significant upregulation of key players in NF-κB 
signaling relative to exceptional responders, which may explain their poorer prognosis. 
An alternative way to view this is that exceptional responders are characterized by less 
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NF-κB signaling, allowing them to remain more sensitive to temozolomide and resulting 
in longer survival times. 
 Nearly all of the GO terms enriched in exceptional responders are associated with 
synaptic plasticity. The process of autophagy intersects with many of the pathways 
known to underlie synaptic plasticity, and it has been proposed that autophagy plays a 
direct role in synaptic plasticity.98,99 Perhaps the tumors of exceptional responders are 
more susceptible to cell death by autophagy, or some other consequence of increased 
synaptic plasticity may confer some advantage. 
 SNCA (synuclein alpha), which is associated with eight of the enriched GO terms, 
may be of particular interest as it has been shown to increase the vulnerability of the GBM 
cell line U373 to cell death.100 SYT11 is of interest as well, as its depletion is known to block 
autophagy.101 The upregulation of SYT11 in exceptional responders may allow autophagy 
to occur. 
 
Enriched KEGG Pathways 
 The top enriched pathways in typical responders are IL-17 and TNF. IL-17 is a pro-
inflammatory pathway that can contribute to tumor progression and metastasis as well as 
resistance to chemotherapy.102 TNF activates the NF-κB pathway and can promote cell 
growth, proliferation, invasion, and angiogenesis.103 Enrichment of either of these 
pathways could contribute to the poorer prognosis seen in the typical response group. 
Cytokine-cytokine receptor interaction and chemokine signaling pathways are also 
implicated, much like in the GO analysis. 
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 In exceptional responders, synaptic transmission appears again, along with MAPK 
signaling, calcium signaling, Parkinson’s disease, and Alzheimer’s disease, all of which 
are related to synaptic plasticity.104–107 Parkinson’s disease pathways being enriched in 
exceptional responders is of particular interest, as several epidemiological studies indicate 
an inverse association between cancer risk and Parkinson’s disease.108 Like synaptic 
plasticity, the enrichment of Parkinson’s and Alzheimer’s pathways also implicates 
autophagy since both of those diseases are characterized by neurodegeneration in which 
autophagy plays a role.109,110 Perhaps the upregulation of these pathways in exceptional 
responders makes the tumors more susceptible to autophagic cell death. 
 
Correlation Results 
 No gene was identified as statistically significant among the results of more than 
one data type. However, the trends seem to match and the correlation results corroborate 
this. In many cases, the r and ρ values reported in this study would be considered weak 
to moderate, but in the case of the correlation between methylation and gene expression, 
correlation coefficients with the magnitudes identified in this study are quite good. 
Typically, correlation coefficients for methylation and gene expression are rather modest, 
right around -0.3, which has been attributed to noise, sample heterogeneity, and other 
regulatory events besides methylation.111 This means that the relationship between 
methylation and gene expression in this study is a strong negative correlation, as the 
correlation coefficients are of a larger magnitude than 0.3, especially when the gene list 
being assessed is narrowed to only the significant results list. The correlation between 
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copy number and gene expression is not as strong, but this is not surprising given the 
large number of other regulatory mechanisms that could be affecting gene expression, as 
well as the fact that nearly all of the significant copy number aberrations were only gains 























Sex as a Confounding Variable 
 Although sex was a confounding variable for survival between the typical and 
exceptional response groups, it was not confounding in the full dataset. Although the 
incidence of GBM is higher in males, sex has not been found to be predictive of prognosis 
or survival in GBM.112 For these reasons, it seems likely that the identification of sex as a 
confounding variable is an artifact or just occurred by chance for this particular dataset. 
 Although it is unlikely that sex is truly predictive of survival in GBM, the 
distribution of sexes between the two response groups was significantly skewed 
nonetheless, and this had to be accounted for. When possible, this problem was addressed 
by performing sex-specific analyses in addition to the full analysis of typical versus 
exceptional responders (as in the copy number and expression analyses), and then only 
results identified in all three analyses or only in the full analysis and not in the sex-specific 
analyses were included in the final results. When there was not a sufficient number of 
samples available to perform sex-specific analyses (as in the methylation analysis), sex 
chromosomes were excluded from the analysis. These efforts seem to have been successful 
in controlling for the differential distribution of sex in the response groups. Prior to 
performing the methods to control for sex, many results were genes on the X or Y 
chromosome or were otherwise associated with sex. This was particularly true in the 
methylation analysis, in which most of the results were on the X chromosome prior to 
controlling for sex. This was likely due to X inactivation in females, which is the process 
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by which one X chromosome is silenced via heavy methylation.113 After the methods to 
control for the differential distribution of sexes were applied, the final results for all the 
data types were largely biologically relevant and not associated with any sex-specific 
biological processes. 
 
Data Types with No Significant Results 
 Of all the data types analyzed, the miRNA expression analysis and the protein 
expression analysis were the only ones that did not yield any significantly differentially 
expressed results. In the case of protein expression, this is likely largely due to both the 
small sample size and the relatively small number of proteins assessed. While RPPA 
assesses expression of quite a large number of proteins compared to other techniques such 
as western blots, it is still only a very small fraction of the proteome (222 antibodies). The 
only overlap between the significant results from other data types and the list of proteins 
assessed by RPPA is CDKN2A, which had a greater magnitude of copy number loss in 
typical responders. Protein expression results indicate that typical responders had a lower 
mean relative expression of CDKN2A (0.496 for typical and 1.095 for exceptional), as 
expected based on the copy number analysis, but this result was not statistically 
significant. Between the low degree of overlap and the small number of patients for whom 
protein expression data were available, it is not surprising that no significant results were 
identified. As for the miRNA expression, the sample size was suitable and the number of 
miRNAs assessed was reasonable, and yet no significant results were identified. While it 
has been established that aberrant expression of a variety of miRNAs relative to normal 
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expression is characteristic of GBM overall, it is possible that these are simply not 
differentially expressed between the response groups in this dataset. 
 
Trend of Disorder in Typical Responders 
 The results from several analyses suggest that typical responders are characterized 
by a loss of transcriptional control and aberrations of a greater magnitude than 
exceptional responders. The copy number analysis revealed that while most copy number 
alterations are consistent across both response groups, the magnitude is consistently 
larger in the typical responders. Methylation levels at CpG sites with a large degree of 
variation between the response groups are almost invariably lower in typical responders, 
suggesting that exceptional responders have increased gene silencing and transcriptional 
control. While both response groups tend to be characterized by many of the same 
alterations, the changes tend to be more severe in typical responders. The somewhat less 
severe alterations in exceptional responders may be contributing to their better prognosis. 
 
Correlation Trends 
 No single gene was identified as statistically significant in more than one data 
type. However, the trends for most of the significant results are concordant. For example, 
genes with significantly higher promoter methylation tend to have lower expression 
levels even though the expression comparison does not reach statistical significance. 
Genes with copy number gains tend to have higher expression, genes with copy number 
losses tend to have lower expression, and so on. The negative correlation between 
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methylation and gene expression among the significant results list is particularly 
convincing, with r and ρ values ranging from -0.4484 to -0.6065, indicating a strong 
relationship between increased methylation and reduced gene expression among genes 
that are altered between typical and exceptional responders.  
 
Frequently Affected Pathways and Biological Processes 
NF-κB 
 NF-κB was determined to be upregulated in typical responders relative to 
exceptional responders in several analyses. Four of the five groups of genes associated 
with enriched KEGG pathways in typical responders include NFKB1, a key player in the 
NF-κB pathway. One of these enriched pathways is the TNF signaling pathway, which 
activates NF-κB signaling, resulting in proliferation and protection from death by 
apoptosis.103 NFKB1 was also an important player in two of the three enriched GO terms 
in typical responders. Several other genes associated with NF-κB signaling were present 
in the significant results, including IL6, BCL3, and TRIB2. Enrichment of this pathway in 
typical responders may be partially responsible for their worse prognosis. Upregulation 
of the NF-κB pathway is common in many cancers, including GBM, so perhaps a better 
way to view this result is that exceptional responders tend to have less upregulation of 







 The top KEGG pathway result, nearly all of the GO terms, and all of the GSEA 
gene sets enriched in exceptional responders are directly related to synaptic plasticity, 
which is the ability of neurons to change the quantity and strength of their synapses. 
Astrocytes are heavily involved in this process.114 Autophagy pathways and synaptic 
plasticity pathways have a lot of overlap, and it has been proposed that autophagy plays 
a direct role in synaptic plasticity.98,99 Perhaps the upregulation of genes related to synaptic 
transmission in exceptional responders leaves their tumor cells more susceptible to 
autophagy. Glioblastoma cells are more likely to respond to autophagy-inducing 
therapies than to apoptosis-inducing therapies115, and it is possible that this characteristic 
of expectational responders increases this positive response even further. It may also be 
the case that some other aspect of synaptic transmission and synaptic plasticity confers a 
benefit to exceptional responders. 
 
Neurodegenerative Diseases 
 Both Alzheimer’s disease and Parkinson’s disease pathways were enriched in 
exceptional responders based on the KEGG analysis. Both of these diseases are 
characterized by cell death through autophagy and/or apoptosis.109,110 Some studies 
indicate that higher risk of Parkinson’s disease is inversely associated with cancer risk.108 
While activation of these pathways is certainly detrimental in neurodegenerative diseases, 
in cancer it may result in increased sensitivity to treatment. Tumors of exceptional 
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responders with upregulation of these pathways may retain the ability to undergo cell 
death in response to treatment, granting exceptional responders a better prognosis. 
 
Cytokine Signaling 
 Cytokines are a group of small proteins that are important in cell signaling and are 
especially important in the immune system. Pro-inflammatory cytokines are known to 
promote cancer cell proliferation in many cases.116 Several pro-inflammatory cytokines 
and associated pathways were implicated in typical responders throughout this study, 
including IL6, CCL20, CXCL8, TNF signaling, and IL-17 signaling. The top enriched GO 
term in typical responders was the regulation of cytokine biosynthetic processes and 
enriched KEGG pathways in typical responders included cytokine-cytokine receptor 
interaction and chemokine signaling pathway, in addition to the aforementioned TNF and 
IL-17 signaling pathways. CXCL8 and CCL20 are perhaps the most prominent of these 
results, as they were the only two genes with significantly higher expression in typical 
responders compared to exceptional, and at least one of them is present in every group of 
genes associated with the enriched KEGG pathways in typical responders. CXCL8 was 
also found to be predictive of survival outcome in the full TCGA GBM dataset of 408 
patients, with increased expression associated with significantly shorter survival times. 
Typical responders are characterized by upregulation of pro-inflammatory cytokine 
signaling, and exceptional responders do not share this trait. This lack of pro-





 The significant results generated in the copy number, methylation, gene 
expression, and pathway analyses conducted in this study have provided some insight 
into the molecular differences between typical and exceptional responders in GBM. 
Upregulated pathways and processes in typical responders are consistently associated 
with more aggressive tumor phenotypes that may be partially responsible for the poor 
response to treatment that most GBM patients exhibit. Upregulated pathways and 
processes in exceptional responders may indicate that the small number of patients who 
respond very well to treatment have tumors that have retained the ability to undergo cell 
death by autophagy, which may make the standard GBM treatment of temozolomide 
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